Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors
Q. Sun et al., Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors, BLOOD, 94(6), 1999, pp. 1943-1951
Human interleukin-5 (IL-5), granulocyte-macrophage colony-stimulating facto
r (GM-CSF), and IL-3 are eosinophilopoietic cytokines implicated in allergy
in general and in the inflammation of the airways specifically as seen in
asthma. All 3 cytokines function through cell surface receptors that compri
se a ligand-specific alpha chain and a shared subunit (beta(c)). Although b
inding of IL-5, GM-CSF, and IL-3 to their respective receptor alpha chains
is the first step in receptor activation, it is the recruitment of beta(c)
that allows high-affinity binding and signal transduction to proceed. Thus,
beta(c) is a valid yet untested target for antiasthma drugs with the added
advantage of potentially allowing antagonism of all 3 eosinophil-acting cy
tokines with a single compound. We show here the first development of such
an agent in the form of a monoclonal antibody (MoAb), BION-1, raised agains
t the isolated membrane proximal domain of beta(c). BION-1 blocked eosinoph
il production, survival, and activation stimulated by IL-5 as well as by GM
-CSF and IL-3. Studies of the mechanism of this antagonism showed that BION
-1 prevented the high-affinity binding of I-125-IL-5, I-125-GM-CSF, and I-1
25-IL-3 to purified human eosinophils and that it bound to the major cytoki
ne binding site of beta(c). Interestingly, epitope analysis using several b
eta(c) mutants showed that BION-1 interacted with residues different from t
hose used by IL-5, GM-CSF, and IL-3. Furthermore, coimmunoprecipitation exp
eriments showed that BION-1 prevented ligand-induced receptor dimerization
and phosphorylation of beta(c), suggesting that ligand contact with beta(c)
is a prerequisite for recruitment of beta(c), receptor dimerization, and c
onsequent activation. These results demonstrate the feasibility of simultan
eously inhibiting IL-5, GM-CSF, and IL-3 function with a single agent and t
hat BION-1 represents a new tool and lead compound with which to identify a
nd generate further agents for the treatment of eosinophil-dependent diseas
es such as asthma. (C) 1999 by The American Society of Hematology.